Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder
University of California, Los Angeles
Summary
This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the clinical effects of G-PACBT on depressive symptoms and psychosocial functioning.
Eligibility
- Age range
- 21–60 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Ages 21-60, * Fluent in English * Able to swallow capsules, * Meets for a current major depressive episode or a history of major depressive episodes based on the DSM-5 criteria (American Psychiatric Association, 2013), * Active current depressive symptoms (i.e., scores \>16 on the Hamilton-Depression Rating Scale covering the prior 2 weeks; Hamilton, 1986), * Have an identified support person (i.e., trusted adult friend or relative) who can pick up the individual from UCLA Semel Institute and drive individual home following psilocybin sessions, * For women of child-beari…
Interventions
- DrugPsilocybin (drug)
Two administrations of psilocybin, administered orally (a 10mg dose followed by a 25mg dose one month later)
- BehavioralGroup Cognitive Behavioral Therapy
12 sessions of PA-CBT (as manualized by our research team; Weintraub et al., 2023)
Location
- UCLA Semel InstituteLos Angeles, California